Discover our latest insights. 

There are over 7,000 rare diseases that affect very small numbers of patients around the world. Due to the rarity of these conditions, it can be difficult to conduct the research needed to better understand them and to develop effective treatments. One rare disease that has recently come into the spotlight is called Stiff Person Syndrome (SPS). In 2022, global superstar Celine Dion revealed that she had been diagnosed with SPS, which had caused her to stop performing. This year, she released a documentary shedding light on her struggles with SPS symptoms and raising awareness.

Clinical trials are pivotal in cancer treatment innovation, offering new hope and possibilities for patients. At Private Health Management (PHM), we understand that the decision to participate in a clinical trial can be daunting. Our team of experienced research scientists, clinicians, and care coordinators provide expert, independent advice tailored to each patient’s individual needs and care goals. By demystifying the process and highlighting the potential benefits, we strive to make clinical trials a viable and accessible option for patients who can benefit the most.

Alzheimer’s disease affects more than 6 million Americans and is the leading cause of dementia, but it can be challenging to correctly diagnose. Results of a new study suggest that a simple blood test may be able to quickly and accurately improve Alzheimer’s diagnosis. Private Health Management (PHM) is committed to providing our clients with Alzheimer’s with the most advanced care and we have helped them receive this useful test. Explore key takeaways from this promising study.

Each June, over 40,000 oncology professionals, including physicians, researchers, patient advocates, and pharmaceutical representatives attend the American Society of Clinical Oncology (ASCO) meeting in Chicago, IL. This meeting is considered the premiere forum for the presentation of the most recent scientific progress made in cancer research. Private Heath Management’s research scientists attend dozens of presentations each year to stay current on the latest clinical data and emerging technologies. Here are some of the most exciting developments from ASCO 2024.

On July 29, the U.S. Food and Drug Administration (FDA) approved Guardant Health’s Shield™ test, the first colorectal cancer screening test that analyzes a blood sample to identify molecular signs of cancer. The latest research shows that early detection of cancer improves treatment outcomes and survival rates and experts predict that having a non-invasive option will help to screen more patients and catch colorectal cancer at treatable stages.